Introduction
The biological impacts of benzene have been studied in humans and in animal models for most of this century. This review concentrates on several aspects of the biology of benzene. We discuss its metabolic fate, our current understanding of the mechanism by which it produces its effects, attempts to develop pharmacokinetic models for its disposition, and, finally, we discuss the impact of benzene on humans. Our aim is not only to present a synopsis of the literature on benzene toxicity, but also to challenge investigators to initiate new studies that will lead to a thorough understanding of benzene as a hazardous agent in our environment.
Metabolism
Benzene is the smallest and most stable aromatic hydrocarbon. In order to be toxic, benzene must be metabolized to reactive intermediates (1) (2) (3) . Available studies suggest that benzene toxicity is mediated by multiple metabolites acting on multiple cellular targets (4) . This discussion briefly reviews benzene metabolism, mechanism of metabolite formation and the chemical reactivity of benzene metabolites in relation to cellular targets. For recent detailed reviews, the reader is referred to Kalf (5) , Snyder and Chatterjee (6) , and Yardley-Jones et al. (7) .
Metabolic Pathways
The major metabolism of benzene in vivo takes place in the liver and consists of the formation of ring-hydroxylated compounds ( Fig. 1) . Early studies conducted in rabbits (8) (9) (10) showed that benzene is hydroxylated to phenol, catechol, hydroquinone, and 1,2,4-benzenetriol, which are excreted as ethereal sulfates and glucuronides in the urine (Fig. 2) . Work by Jaffe (11 ) and other investigators (12) showed that benzene metabolism also involves ring opening as indicated by the urinary excretion of trans,trans-muconic acid, a ring-opened, six carbon diene dicarboxylic acid. The formation of trans,trans-muconic acid (muconic acid) was definitively established by Parke and Williams (9) , who demonstrated the excretion of [ 4C]muconic acid in the urine of rabbits dosed with ['4C]benzene.
The metabolic pathways of benzene originally determined in rabbits were subsequently established in rats and mice (13) (14) (15) (16) . Two metabolic pathways appear to be involved, one leading to ring-hydroxylated compounds and one that involves ring opening of benzene. The hydroxylated compounds are further metabolized to glucuronide or sulfate conjugates, which are excreted in the urine. These conjugates are detoxification products, because conjugation leads to their elimination and prevents the formation of toxic intermediates derived from hydroxylated benzene metabolites. Conjugation with glutathione and urinary excretion of the mercapturic acid is an additional pathway that detoxifies benzene oxide, the initial reactive intermediate formed during metabolism of benzene to phenol (discussed below). The urinary metabolite muconic acid is at present the only known ring-opened metabolite formed from benzene in vivo. This metabolite is a detoxification product of trans,trans-muconaldehyde, a reactive intermediate formed during microsomal metabolism of benzene via ring opening (17) .
The initial step in the metabolism ofbenzene results in the for- mation of phenol. Numerous in vitro studies utilizing cellular fractions or reconstituted purified enzyme systems indicate that this step involves metabolism of benzene by cytochrome P-450 monooxygenase (18) . Benzene is a substrate for isozyme P-450 IIEI (19) , and P-450 monooxygenases are also active in the metabolism of phenol to hydroquinone and catechol (20) . The formation of phenol is believed to involve the intermediate formation of benzene oxide followed by rearrangement to phenol (21). Alternatively, phenol can also be formed from benzene oxide by acid-catalyzed opening of the epoxide ring, followed by o-BENZOOUINONE aromatization via loss of a proton. Figure 2 shows that the urinary metabolites of benzene may include the glucuronic and sulfate conjugates ofthe phenolic metabolites, the premercapturic and the mercapturic acids derived from benzene oxide, the mercapturic acid derived from pbenzoquinone, N-7-phenylguanine, derived from a DNA adduct of benzene, and muconic acid.
Microsomal metabolism of benzene leads to the formation of tmans,trmns-muconaldehyde (Fig. 3) , a reactive ring-opened, sixcarbon diene dialdehyde (17 (9, 36, 37) .
Reactive Metabolites in Benzene Metabolism
The major metabolism of benzene takes place in the liver where it is mediated by cytochrome P-450 monooxygenase. Metabolism ofbenzene by cytochrome P-450 (38) who identified N-7-phenylguanine in the urine of rats exposed to 500 ppm benzene for 8 hr. This adduct is most likely formed by reaction of benzene oxide with the N-7 of guanine, followed by aromatization ofthe benzene ring via loss of a molecule of water and subsequent depurination of the adduct from DNA. Although benzene is also metabolized to phenol and other hydroxylated metabolites inthe bone nmarrow (39) , P-450mediated metabolismin this tissue occurs to arelatively limited extent. This isduetolowlevelsofthis enzyme system in the bone maffow compared with liver. 295 Indirect evidence indicates that muconaldehyde may be another reactive metabolite formed in the liver (17) . In addition, the reactive intermediatesp-benzoquinone and o-benzoquinone may be formed in this tissue by oxidation of hydroquinone and catechol, respectively. These reactive quinone metabolites and muconaldehyde are direct-acting alkylating agents capable of reacting with cellular nucleophiles, including DNA (40, 41) . Numerous in vitro and in vivo studies indicate that these metabolites are genotoxic (42) (43) (44) (45) . Once formed in the liver, it is unlikely that they survive long enough to reach the bone marrow. It is possible, however, that reactive benzene metabolites, similar to other reactive intermediates, may be bound to carriers that release them after transport to the target tissue. Reactive intermediates may also be conjugated to form less reactive intermediates or "storage forms" which, after transport, release the reactive metabolite through deconjugation. A third possibility germane perhaps to muconaldehyde may consist of metabolism to a less reactive compound, i.e., a mixed aldehyde alcohol MUC analog (Fig. 3) , which itself may be hematotoxic or is subsequently reactivated in the target tissue by metabolism to the original reactive metabolite, i.e., muconaldehyde.
The bonemarrow has been shown to accumulate hydroquinone and catechol (46, 47) , two phenolic metabolites of benzene. As discussed above, bone marrow, unlike the liver, contains low levels of cytochrome P-450 and high levels of peroxidases. Phenolic compounds are excellent electron donors for the peroxidase-mediated metabolism of hydrogen peroxide. Studies by Eastmond et al. (48, 49) and Sadler et al. (50) have shown that phenol, catechol, and hydroquinone are excellent substrates for myeloperoxidase, a peroxidase present in high concentrations in the bone marrow. During myeloperoxidase metabolism, these phenolic metabolites undergo one-electron oxidation and covalent binding to protein. The reactive species involved in the binding are presumably radical intermediates, such as the semiquinone free radical of hydroquinone, which are formed during one-electron oxidation.
Para-benzoquinone is a reactivec3,,3unsaturated diketone that has been implicated in bone marrow toxicity (51, 52) . Phenol and catechol have been shown to stimulate the myeloperoxidase dependent conversion of hydroquinone to p-benzoquinone (52, 53) . Based on these studies, Smith et al. (54) proposed a twostep mechanism of benzene toxicity that involves metabolism to phenolic compounds in the liver, transport and accumulation of these compounds in the bone marrow, followed by myeloperoxidase-mediated conversion of hydroquinone to pbenzoquinone in a process stimulated by phenol and possibly catechol. This mechanism ofp-benzoquinone formation does not exclude a similar involvement by prostaglandin (H) synthetase and eosinophil peroxidase in benzene toxicity (55) .
Mechanisms of Benzene Toxicity
The most frequently observed toxic effect of benzene in humans and in animal models used for the study of benzene toxicity has been bone marrow depression leading to aplastic anemia (14) . The correlation between the effects of benzene exposure in humans and the effects produced in animal models was demonstrated by Santesson in 1897 (56) , Selling in 1916 (57) and Weiskotten et al. in 1916 and 1920 (58,59 ). As a result many studies in animals have been aimed at uncovering the mechanism ofbenzene toxicity for the purpose of applying these observations toward an understanding of the human disease.
During the latter half of this century, it has become apparent that benzene also causes chromosomal abnormalities indicative of genetic damage (60) (61) (62) (63) (64) . Attempts to demonstrate mutagenic activity of benzene have been largely unsuccessful (42) , but benzene is a human leukemogen (65) and causes solid tumors in animals (66) (67) (68) . Unfortunately, there is no convenient model for studying the mechanisms by which benzene produces neoplastic effects in animals. Although each of these effects, i.e., aplastic anemia, chromosome damage, and carcinogenesis, are indicative of the ultimate impact of benzene on bone marrow, the relationship between these phenomena and the mechanisms by which they are initiated remain to be fully understood. This section describes the effects of benzene in model systems, discusses the mechanisms by which these effects occur as we currently understand them, and points out data gaps, which when filled may help us to a better mechanistic appreciation ofthe biological impact of benzene.
Hematopoiesis
The mechanism of benzene toxicity has ben examined on the basis of its effects on stem and progenitor cells in the bone marrow as well as its effects on the hematopoietic microenvironment. Hematopoietic stem cells in the bone marrow give rise to the major cell types in the circulation, i.e., erythrocytes, thrombocytes, and the several major subdivisions which comprise the leukocytes (69) . The self-renewing stem cells which reproduce themselves, also yield a cell committed to eventual maturation to a circulating cell. Growthfactors direct committed cells to enter the maturational process, e.g., in the red cell line the committed erythroid cell is sensitive to the initiating action of erythropoietin. To assure that the level of mature cells is constant despite the regular destruction of aged erythrocytes requires that the marrow provide a mechanism for both maturation from the morphology of the primitive stem cell to that of the mature circulating erythrocyte, plus a mechanism for amplification to sustain the requisite number of circulating erythrocytes, i.e., approximately 5 million cells/4L in humans with a survival time of 120 days.
Thus, a complex series of biosynthetic events results in the passage of these cells through several defined morphological stages, during many of which the cells undergo mitosis to increase total numbers. A related, but unique process leads to megakaryocyte production and eventual release of platelets in large numbers (approximately 250,000/L in humans with a survival time of 10 days). Fewer leukocytes, e.g., between 5 and 12,000 cells/A4L in most species, are required. However, the process is complicated by the need for several different forms including granulocytes, lymphocytes, monocytes, etc., each divided into several functional and morphological subtypes and with differing lifetimes. These also undergo a series of steps directed by cytokines or other growth factors involving both maturation and amplification.
The hematopoieticmicroenvironment is composed of a variety of cells and structures including endosteal cells, fibroblasts, reticuloendothelial cells (monocytes and macrophages), fat cells, and bone and sinusoids of the marrow and is responsible for sustaining stem and progenitor cells. Proteins such as erythropoietin, colony-stimulating factors, the interleukins and related cytokine mediators are products of microenvironmental cells and play key roles in directing these events (69) . In the absence of the microenvironment, primitive blood cells cannot mature.
Effects of Benzene
Many studies have shown that treatment of whole animals with benzene leads to decrements in the levels of circulating blood cells (14) . Mechanistic studies have benefited from the development of a variety of in vitro techniques. Thus, the bone marrow of animals exposed to benzene using various exposure protocols can be removed and grown in culture to explore the effects of benzene on specific cell lines at more or less specific stages of maturation. Several laboratories have reported on decreases in the multipotential hematopoietic stem cell (spleen colony forming unit or CFU-S) in mice after a variety of exposure protocols (70) (71) (72) (73) . Similar effects have been observed using the early granulocyte-macrophage CFU-C assay (72, 74) . Decreases have also been observed using the erythroid colony-forming unit (CFU-E) and the burst-forming colony unit (BFU-E) assay, each of which defines a committed stem cell early in erythrocyte development (75, 76) . Exposure of mice in utero to benzene at relatively low concentrations resulted in decrements in bone marrow colony forming units postnatally (77, 78) . These studies indicate that benzene exerts a significant impact on both primitive and early committed stem cells.
In addition to the effects ofbenzene on stem cells and committed stem cells, both morphological and functional evidence has linked benzene to impairment of the processes ofmaturation and amplification. Pronormoblasts, normoblasts, and reticulocytes appear successively at 24, 48, and 72 hr after reinitiation of red cell development by erythropoietin (79) . Synthesis of hemoglobin, including the incorporation of iron, occurs only between the pronormoblast and reticulocyte stage of cellular differentiation (80, 81) . One method to observe the effects ofchemicals on various stage of erythropoiesis in vivo involves administration of 59Fe intravenously followed by sampling 1 day later of the red cells for incorporation of the iron into hemoglobin (82, 83) . This provides a functional measurement of the reticulocyte pool.
Treatment with chemicals at various times before iron administration resulted in a decrease in iron uptake. These data indicate an impairment in red cell development, provided it is known that the chemical did not interrupt reticulocyte hemoglobin synthesis. In the case of benzene (82, 83) hemoglobin synthesis proceeds normally. The maximum decrease in iron uptake following administration ofbenzene occurred 48 hr before iron administration, a time at which the reticulocytes are at the earlier pronormoblast stage of development. Normoblast development was also inhibited but no effect was observed in these studies on committed stem cells nor on reticulocytes. Taken (86) . Incubation ofbone marrow cells with benzene before injection into irradiated mice had no effect on spleen colony formation. Frash et al. (86) concluded that the hematopoietic microenvironment was damaged as a result of benzene treatment.
Effects of Benzene Metabolites
It appears that benzene toxicity occurs only under conditions that permit the production of benzene metabolites. Thus, animals were protected from benzene toxicity after partial hepatectomy, which reduced total benzene metabolism in vivo and resulted in a decrease in covalent binding ofmetabolites in bone marrow (2) . his was not the first suggestion that benzene metabolites play a critical role in toxicity. Parke and Williams (9) , in their pathfinding report suggested that the phenolic metabolites of benzene might be responsible for benzene toxicity. A number of investigators subsequently attempted to identify the toxic metabolites ofbenzene. Both Bolscak and Nerland (3) and Snyder and co-workers (87) (88) (89) have studied the effects of benzene metabolites on 59Fe uptake in mice and found that hydroquinone and catechol (50-100 mg/kg) are more potent in decreasing iron uptake than phenol. Para-benzoquinone, the metabolic product of hydroquinone, is more potent than hydroquinone. Muconaldehyde andp-benzoquinone were effective in inhibiting iron uptake in the range of 1-4 mg/kg.
Several studies have focused on the possibility that benzene toxicity is the result of synergistic interactions among benzene metabolites. Eastmond et al. (49) studied the effect of administering a combination of phenol and hydroquinone and reported that the combination enhanced the ability ofeach to inhibit bone marrow function. Possible explanations for the interaction between hydroquinone and phenol include the preferential conjugation of phenol by sulfate and glucuronide leading to a greater effective concentration of free hydroquinone, the stimulation of the production ofreactive metabolites from hydroquinone by phenol, or both. The same interaction was also observed in Snyder's laboratory (87, 88) using the 59Fe uptake technique.
Guy et al. (89) studied the effects of combining muconaldehyde plus either hydroquinone orp-benzoquinone on iron uptake into erythrocytes. They reported that when the binary mixtures were administered together at doses of either which were ineffective in reducing iron uptake, the combined effect was to severely inhibit red cell production. Higher doses also indicated interaction. Multiple regression analysis was used to study the contributions of the components of the binary mixtures. The results suggested that in inhibiting red cell production, muconaldehyde and hydroquinone react at the same site. Muconaldehyde andp-benzoquinone appear to act at two sites. The nature of these sites are not yet known, but these studies suggest that benzene toxicity is the result ofthe interaction between benzene metabolites rather than the effect of a single metabolite acting independently.
The effects of benzene metabolites on the microenvironment have also been studied. Gaido and Wierda (90) (91) (92) 
studied the mutagenic activity of 13 benzene metabolites using strain TA1535. In the absence of S9, trans-1,2-benzenedihydrodiol and benzene diol epoxides were mutagenic. Dihydrodiol dehydrogenase, which converts the dihydrodiol to catechol, protected against the mutagenic effect. It is the postulated, but not demonstrated, that the dihydrodiol can be converted to a series ofisomeric diol epoxides via a further epoxidation. The anti-diol epoxide was a mutagen in strains TA97, TA98, TA100, TA102, TA104, and TA1535. In V79 cells, the anti-diol epoxide also induced sister chromatid exchange, acquisition of6-thioguanine resistance and ouabain resistance, and micronuclei. Although the anti-diol epoxidehasnotbeendemonstratedtobeametabolicproductofbenzene as yet, the potential for its formation remains, and itmight be one ofthe most mutagenic products derived from benzene.
Other metabolites effective in the V79 cells were 1,2,4-trihydroxybenzene, hydroquinone, catechol, and the trans-1,2-dihydrodiol which elevated resistance to 6-thioguanine. The most striking effect in these studies, however, was both the potency and great effectiveness ofp-benzoquinone in increasing the frequency of 6-thioguanine resistance while having no effect on ouabain resistance, and producing no chromosome damage in V79 cells. Furthermore, p-benzoquinone was relatively ineffective in Salmonella.
The potential genotoxic activity of trans,trans-muconaldehyde, a chemically reactive ring opening product of benzene in microsomal preparations, was investigated in studies by Witz and co-workers (44, 45) . Trans,trans-muconaldehyde is generally highly toxic to cells in vitro. It is an active mutagen in V79 cells but is weakly mutagenic in Salmonella (44) . In CHO cells trans,trans-muconaldehyde is a potent clastogen (37, 45) . Thus, it appears that ifbenzene can undergo metabolic activation, some of its metabolites, both ring closed and ring opened, can mediate mutagenic events.
Chromosome Damage
Since the first reports of Pollini and co-workers (98, 99) , benzene has been known to produce chromosome damage. They cultured both bone marrow cells and peripheral lymphocytes from patients displaying severe benzene hemopathy and reported a high rate of aneuploid cell production. Subsequently, there were many reported observations ofchromosome aberrations in blood from workers exposed to benzene. Notable among these were the reports of Forni and her collaborators (60, 61) , who observed chromosome aberrations in a group ofworkers exposed to benzene at a greater frequency than workers exposed to toluene (60) . Follow-up studies ofthese workers revealed that both stable and unstable benzene-induced chromosome aberrations occurred. The unstable variety eventually disappear, whereas the stable form persist and may relate to the eventual development of leukemia. Erexson et al. (100) reported that low-dose exposure to benzene (10-28 ppm) over 4-6 hr produced sister chromatid exchanges (SCE) in peripheral mouse B-lymphocytes. Tice et al. (63) demonstrated the production of sister chromatid exchanges in mice after short-term exposure to high concentrations of benzene. The effect was exacerbated when the mice were pre-treated with phenobarbital, presumably because at these high doses phenobarbital induces an enzyme that can efficiently bioactivate benzene. Although partial hepatectomy was not protective, co-administration of toluene reduced SCE by 90%. Witz et al. (45) reported that administration of trans,trans-muconaldehyde caused SCE in B6C3F, mice. The data suggested that benzene metabolites play a significant role in producing SCE.
In cultured human lymphocytes in vitro, it is clear that benzene metabolites induce SCE (101) . Phenol, catechol, and hydroquinone produced SCE in a dose-dependent manner in the absence of added metabolic activation, and the effect was prevented by glutathione. Sister chromatid exchanges were induced with the following order of potencies: catechol > 1,4-benzoquinone > hydroquinone, 1 (72) . Hydroquinone and pbenzoquinone interfere with GTP-tubulin binding by alkylating SH groups (109, 110) . Another protein that is inhibited by benzene metabolites, hydroquinone, and p-benzoquinone, but not phenol or catechol, is mitochondrial DNA polymerase--y, which also possesses a sulfhydryl group at the active site (111) . The binding of benzene metabolites to these critical proteins may play a role in benzene toxicity.
The observations of chromosome damage described above suggest that the binding ofbenzene metabolites to DNA may also represent a significant event in benzene toxicity in view of the chromosome damage discussed above. Lutz and Schlatter (108) exposed rats to either [14C]-or [3H]benzene by inhalation and found that liver nuclear DNA contained covalently bound benzene residues, although Lutz (112) noted that when compared with other carcinogens, relatively little radioactivity derived from benzene was bound to DNA. Rushmore et al. (113) took advantage of the properties of mitochondrial DNA to study DNA binding by metabolites ofbenzene. The mitochondrion contains no mechanism for DNA repair and contains a small circular DNA. Furthermore, the presence of a cytochrome P-450 monooxygenase in mitochondria capable of metabolizing benzene facilitated production of reactive intermediates (114) . Seven potential DNA adducts on deoxyguanosine and one on deoxyadenosine were observed, and structures have been proposed for one of the adducts on deoxyguanosine (40) and for the deoxyadenosine adduct (115) . Neither thymine nor cytosine adducts were investigated.
Schlosser et al. (105) investigated the oxidation of hydroquinone by prostaglandin H synthetase and found that whereas 1,4-benzoquinone, the oxidation product of hydroquinone, was bound to cysteine or DNA, inhibition of the enzyme by indomethacin inhibited both types of binding as well as micronucleus formation (104) and benzene-induced myelotoxicity (116) .
The low level of binding has made it difficult to detect DNA adducts in vivo. However, use has been made of the 32P-postlabeling technique to measure benzene related adducts because of its great sensitivity. Bauer et al. (117) reported on DNA adduct formation in rabbit liver. Snyder et al. (87) suggested that DNA adducts are formed in the bone marrow ofbenzene-treated rats. Using the same method, Reddy et al. (118) was unable to detect DNA adducts from benzene in the Zymbal gland, a target for the carcinogenic activity of benzene in the rat, or in bone marrow, presumably the target for leukemogenic activity. Further research is needed to determine the role of DNA binding of benzene metabolites in benzene toxicity and carcinogenesis.
Carcinogenesis
From the mechanistic point of view, benzene-induced carcinogenic events have been difficult to study because of the lack of a convenient animal model. Chronic exposure of rats and mice to benzene by inhalation (119) suggests that benzene might induce acute and chronic myelogenous leukemia and thymic lymphoma in these species. Large scale, chronic exposure studies by Maltoni et al. (66, 67) in rats and mice using inhalation or oral administration revealed the appearance of Zymbal gland tumors as well as a variety of other cancers. These results were confirmed and extended in a National Toxicology Program study (68) . However, these studies have not led to the development of models of use to study the mechanism of leukemogenesis. A more promising approach came from Cronkite et al. (120) , who reasoned that the difficulty in producing leukemia during chronic exposure is because benzene is an inhibitor of cell replication, a process essential to the development of leukemia. Therefore, these workers treated mice for 16 weeks with 300 ppm ofbenzene and then ceased exposure. Subsequently, none of 88 control mice demonstrated neoplasms, but 8 of 90 benzene-exposed mice displayed lymphoma/leukemias (120) . This method has yet to be fully exploited in the study of the mechanism of benzene-induced leukemia.
Prevailing theories suggest that initiating events in carcinogenesis may be covalent binding of reactive intermediates to DNA or oxidative damage of DNA. Subsequent attempts to either repair or replicate the DNA propel the cascade of events termed carcinogenesis. Furtherance ofthis process is thought to require the intervention of one or more promotional steps that stimulate proliferation of the genetically altered cells. Alternatively, so-called epigenetic events may lead to carcinogenesis. The mechanism ofbenzene toxicity has yet to be defined within these frameworks.
If we assume that a genetic alteration underlies the mechanism of benzene-induced carcinogenesis, we can look toward the results of the genotoxicity studies cited above as indicators of the pathway toward neoplasia. Thus (18) repetitively exposed mice or rats to 100 or 300 ppm ofbenzene for 20 days and sampled the blood for benzene on days 1, 6, and 20. At higher doses mice achieved greater increases in blood levels of benzene than the rats. The mice also displayed a greater elimination rate constant than the rats. The rate ofblood benzene disappearance from mice at the high dose shifted from monoexponential to biexponential between the 6th and 20th day, which may have been due to enzyme induction ofbenzene hydroxylase, i.e., cytochrome P-450 IIEI.
More recent approaches have attempted to factor metabolism into physiologically based pharmacokinetic models ofthe fate of benzene and to develop a method for extrapolating from animal models to humans. Beliles and Totman (129) constructed a model using Zymbal gland tumors and blood related cancers as end points and, recognizing the possibilities of synergy and multiple mechanisms, assumed that the combined metabolites represented the "reactive agent." Using largely the data of Sabourin et al. (13) and applying an allometric technique to estimate scaling between species, they suggested that their model, which predicts that a working lifetime exposure (40-45 years) to benzene at 10 ppm would result in 6-14 cases of leukemia/1000, is in good agreement with federal regulatory risk assessments based on epidemiological data.
Physiologically based pharmacokinetic models aimed at relating benzene metabolism and interspecies differences, using both experimental data and simulations, have been developed by Medinsky et al. (130) (133) added the metabolic activity of the bone marrow in the further metabolism of metabolites generated in liver. While each represents an important advance in interpreting the metabolic fate of benzene in relation to the development of benzene-related disease, they all suffer from lack of sufficient data, as well as from variability ofthe data between experimental designs. There generally is difficulty in fitting empirical data to theoretically generated curves, which suggests that the models need to be improved.
Whereas the disappearance ofbenzene from the blood, following administration via any route, can be measured readily, the requirement for metabolism before benzene can produce serious chronic effects, makes modeling difficult because of the uncertainties pertaining to which metabolites are responsible, the relative impact of each, and the potential for multiple target effects.
A large number of metabolites have been described above. Because of their demonstrated, direct effects on bone marrow, pharmacokinetic models have concentrated on hydroquinone, alone or in combination with phenol, and muconaldehyde, and for the most part have assumed that they are formed in liver and transported to the bone marrow. The possibility that some of the critical metabolites are ultimately formed in bone marrow serves to complicate the modeling process. For example, although the metabolites transferred to the bone marrow may be innocuous in themselves, further metabolic activation in bone marrow, perhaps mediated by peroxidases, may generate the ultimate toxic metabolites (135) . Thus, hydroquinone may be released from the liver, free or conjugated, reach the bone marrow by some mechanism, and in its free form may be oxidized to p-benzoquinone by a peroxidase. Muconaldehyde might be formed in bone marrow, and the two working in concert would then produce a toxic effect. The models would have to reflect these factors, as well as take into account the activity of other potential toxic metabolites, if they are to accurately picture the process and be used in risk assessment with accuracy.
Human Impact
Benzene is a ubiquitous pollutant in both the workplace and in the general environment. Ambient concentrations can be detected worldwide, including pristine areas, although at levels much lower than in modern urban societies. Major sources of benzene include petroleum and petroleum products. Levels of benzene in gasoline range from approximately I to 5% . Gasoline serves as a major source of benzene exposure in a wide variety of situations including groundwater contamination through leaky underground storage tanks; air contamination through the evaporation of gasoline in workplaces and in homes; and transdermal exposure when gasoline gets on the skin. The major cause of high-level exposure remains inappropriate use in an unregulated workplace; although control measures are leading to a decreased use of benzene as a solvent and organic synthetic starting block. A major source of personal benzene exposure comes from cigarette smoking (136) , and benzene is also present in sidestream smoke leading to exposure through passive smoking. Although there are measurable amounts ofbenzene in certain foods, these are no longer believed to be a significant source of benzene exposure to the general public, particularly in comparison to indoor air pollution from gasoline and benzenecontaining solvents or from cigarette smoke within the home or the office (137) .
Nonhematological Effects
The odor threshold for benzene is in the range of 4-5 ppm (138) . The acute nervous system toxicity of benzene appears similar to the general anesthetic effects of lipophilic solvents and is assumed to be a direct effect of benzene unrelated to its metabolites. Acute symptoms include drowsiness, lightheadedness, headache, delirium, vertigo, and narcosis. Levels at which acute central nervous system effects become apparent are at least above 100 ppm, an earlier occupational health standard for benzene, although milder effects could conceivably occur at lower levels. Based on structure-activity relationships, benzene might be expected to have acute central nervous system effects similar to alkyl benzenes at a slightly lower dose for benzene. Chronic nervous system effects of benzene have not been clearly demonstrated.
Nonhematological tumors have also been demonstrated in long-term animal studies (139, 140) . However, at present there is no reasonably convincing evidence of nonhematological solid tumors occurring in humans exposed to benzene. A metaanalysis of benzene-exposed populations may be of value in this regard.
Studies of the productive and developmental effects of benzene have shown little aside from hematological effects in the fetus (77, 78) . A more thorough evaluation has been called for by Davis and Pope (141) .
Immune dysfunction as a result of high-level exposure to benzene in laboratory animals has been clearly demonstrated (142) . Lymphocytopenia is an early effect of benzene exposure in animals and in man (143) , and there is also evidence suggesting that the immune system can be affected by benzene independent oflymphocytopenia (144) . However, there is currently no evidence to demonstrate an effect on the immune system of humans exposed to allowable levels of benzene.
Hematological Effects
In humans, as in animal models, the bone marrow is the target of benzene toxicity. A major unanswered question about benzene toxicity concerns its primary localization to the bone marrow, a finding that is almost unique in solvent toxicology. As with many other solvents, benzene is primarily metabolized in the liver, yet despite evidence that metabolism is necessary for bone marrow toxicity, hepatotoxicity is not observed. In essence, there are two different explanations given for bone marrow localization: specificity in the local metabolism of benzene within the bone marrow or particularities in the susceptibility of the bone marrow, as compared to the liver or other organ, to a benzene metabolite or metabolites. For example, Subrahmanyam et al. (135) recently emphasized the potential role of free radicals in benzene toxicity, pointing out that the relatively high level of myeloperoxidase and ofother peroxidases may be responsible for localization ofbenzene toxicity to the bone marrow. In contrast, Goldstein and Witz (145) , noting the relative sensitivity of the bone marrow to chemotherapeutic alkylating agents, have focused on a potential hematologic role for trans,trans-muconaldehyde, an ca,3-unsaturated aldehyde alkylating agent which, although highly reactive, has a sufficient half-life to theoretically travel from liver to bone marrow.
Benzene was initially identified as being a human hematological toxin in the 19th century. Since that time the literature is replete with case studies and series in which fatal aplastic anemia has been reported in individuals exposed to significant levels of benzene (146, 147) . As described above, aplastic anemia is a serious, often fatal, disorder in which the formed elements of the bone marrow are replaced by fat and there is a significant decrement in the formed elements of the blood. Humans may display a decrease in white blood cells (leukopenia), potentially resulting in death due to infection; a decrease in platelet count (thrombocytopenia), potentially resulting in death due to hemorrhage; and a decrease in red blood cell count (anemia). A lesser extent of benzene exposure produces lesser degrees of damage to the bone marrow. The normal human bone marrow has sufficient reserve capacity to be able to produce approximately six times more red blood cells under stress than it does under normal conditions. There is also a wide range of statistically normal values in peripheral blood counts. Thus, earliest forms of bone marrow damage due to a compound such as benzene may not be notable in terms of a decrease in circulating blood counts. As described above, studies in laboratory animals have shown that a decline in colony forming cells indicative of the function and number of bone marrow precursors can be seen with relatively low levels of benzene exposure. In humans, individuals with benzene exposure may initially have a count lower than statistically normal in any one of the formed elements, but with significant exposure, pancytopenia will be observed (146) .
There is a wide range between those blood count levels which are statistically abnormally low and those which produce func- As with any toxicant, there appears to be a variation in the extent to which individuals differ in their sensitivity tobenzene, and some suggestion of a familial tendency (148) . However, there is no evidence of an idiosyncratic low-level sensitivity to benzeneinduced aplastic anemia similar to that observed with chloramphenicol. Interaction with other agents may affect benzene toxicity as described above with respect to ethanol and toluene. Metabolic interaction between toluene and benzene would be expected when exposure occurs to a mixture containing a high ratio of toluene/benzene because toluene is a competitive inhibitor of benzene metabolism (1). However, Sato and Nakajima (128) reported that there is no significant interaction between benzene and toluene with respect to their fate when human experimental exposure was near the threshold limit value.
Neoplastic Effects
LeNoir and Claude reported the first case of benzeneassociated leukemia in humans in 1897 (149) (152, 161, 162) . To obtain a better understanding of the level and pattern of benzene exposure associated with this increased risk of AML, NIOSH has performed one of the most thorough retrospective exposure assessments ever done on a cohort of workers (162) . This exposure analysis has been used as a basis for the current risk assessment of benzene by the U.S. Environmental Protection Agency (EPA). However, it does appear that NIOSH has significantly underestimated the extent of exposure in the Goodyear plants during World WarII (163, 164) , thus leading to some overestimation of the risk of benzene derived from this cohort. However, it should be emphasized that the current EPA risk assessment of benzene has more uncertainty associated with the dose response part of this equation than it does with the exposure. Despite the many arguments concerning the extent to which workers who developed AML were exposed to benzene, the differences all lie within an order of magnitude. In contrast, the dose-response relationship between daily environmental benzene exposure in the range of parts per billion and leukemia has a much larger degree of uncertainty.
This uncertainty can only be resolved by a better mechanistic understanding of benzene leukemogenesis.
More problematic is the potential causal relationship between benzene and lymphopoietic cancers in humans. While in no case is the evidence incontrovertible, there does appear to be more than sufficient grounds to link benzene exposure with multiple myeloma (165) and perhaps with certain forms of non-Hodgkin's lymphoma and acute lymphoblastic leukemia. In the case of multiple myeloma the observations include individual case reports and a statistically significantly increased number of myeloma cases in the Pliofilm cohort that is under study by NIOSH (162, 166) . In the latter cohort, the association has been suggested to be problematic in view of the lack of relationship with the extent of exposure. However, as there is a small number of cases, it is difficult to expect an obvious dose relationship. There is a strong element ofbiological plausibility that supports a causal relationship between benzene exposure and multiple myeloma, as well as other lymphatic neoplasms. Lymphocytes are definitely a target of benzene, with lymphocyte depletion occurring early in the course of benzene exposure (146, 167 Non-Hodgkin's lymphomas represent a grab bag of different diseases. A certain portion of these disorders reflects severe immune depletion as occurs with AIDS or secondary to treatment related to organ transplantation, in which the tumors occur very rapidly, sometimes in less than 1 year. However, there is no clear evidence that benzene produces this form of immune depletion. Non-Hodgkin's lymphoma is observed in certain work groups that have been exposed to solvents or other chemicals, but the evidence that benzene is causally related remains suggestive but uncertain. Similar arguments as to biomedical plausibility could be used to link benzene exposure to acute lymphoblastic leukemia, the leukemia most commonly observed in children. However, in view of the fortunate absence of well-defined populations of children that have been exposed to benzene, it will be particularly difficult to 
